Targeting non-apoptotic regulated cell death (RCD) to treat neurodegenerative diseases
Acta Pharmaceutica Sinica B · 2026-05 · 16 (5) · 2601-2644
DOI: 10.1016/j.apsb.2026.01.040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-05. Verfasst von Wenzhe Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 279 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sichuan Provincial Science and Technology Support Program, National Natural Science Foundation of China, Southwest Jiaotong University.
Abstract (Originalsprache)
Regulated cell death (RCD) is well-known as a controlled form of cell death regulated by one or more cascading signaling pathways. Over the past few decades, increasing evidence has implicated various non-apoptotic forms of RCD in neurons-including ferroptosis, parthanatos, necroptosis, pyroptosis, autophagic cell death, paraptosis, and cuproptosis-in the pathogenesis of neurodegenerative diseases (NDs) and their associated clinical manifestations. We provide an in-depth analysis of the associations between these RCDs and NDs, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), and highlight the potential of modulating non-apoptotic RCD subtypes as neuroprotective targets. Besides, we highlight the crosstalk mechanisms among different non-apoptotic RCDs in NDs and the key targets regulating the crosstalk, which hold significant promise for developing dual-functional inhibitors that precisely modulate the pathological microenvironment and overcome drug resistance. As our understanding of death signaling networks deepens, such strategies may lead to breakthrough therapies for multiple NDs. Moreover, we further discuss the emerging small molecule compounds targeting non-apoptotic RCDs and their current research progress in clinical trials for the treatment of NDs, which may provide novel directions for related drugs. This comprehensive analysis paves the way for future research and therapeutic strategies aimed at harnessing non-apoptotic RCD pathways to mitigate neurodegeneration and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
- Institute of Precision Drug Innovation and Cancer Center, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
- Department of Neurosurgery, The First Hospital of China Medical University, Shenyang 110011, China.
Förderung
- Sichuan Provincial Science and Technology Support Program
- National Natural Science Foundation of China
- Southwest Jiaotong University
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Zhao, W., Lai, Y., Li, Z., Yuan, Z., Wen, Z., & Zhang, L. (2026). Targeting non-apoptotic regulated cell death (RCD) to treat neurodegenerative diseases. Acta Pharmaceutica Sinica B, 16(5), 2601-2644. https://doi.org/10.1016/j.apsb.2026.01.040
Vancouver
Zhao W, Lai Y, Li Z, Yuan Z, Wen Z, Zhang L. Targeting non-apoptotic regulated cell death (RCD) to treat neurodegenerative diseases. Acta Pharmaceutica Sinica B. 2026;16(5):2601-2644. doi:10.1016/j.apsb.2026.01.040
BibTeX
@article{Zhao2026,
author = {Zhao, Wenzhe and Lai, Yue and Li, Zhijia and Yuan, Ziyue and Wen, Zhifeng and Zhang, Lan},
title = {Targeting non-apoptotic regulated cell death (RCD) to treat neurodegenerative diseases},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {5},
pages = {2601--2644},
doi = {10.1016/j.apsb.2026.01.040}
}
EUVIMED